298 related articles for article (PubMed ID: 16144935)
1. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935
[TBL] [Abstract][Full Text] [Related]
2. SMAD4 as a prognostic marker in colorectal cancer.
Alazzouzi H; Alhopuro P; Salovaara R; Sammalkorpi H; Järvinen H; Mecklin JP; Hemminki A; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Apr; 11(7):2606-11. PubMed ID: 15814640
[TBL] [Abstract][Full Text] [Related]
3. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
[TBL] [Abstract][Full Text] [Related]
6. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
Gal R; Sadikov E; Sulkes J; Klein B; Koren R
Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
Ahmed IA; Kelly SB; Anderson JJ; Angus B; Challen C; Lunec J
Colorectal Dis; 2008 May; 10(4):344-51. PubMed ID: 17949449
[TBL] [Abstract][Full Text] [Related]
9. Smad4 and transforming growth factor beta1 expression in patients with squamous cell carcinoma of the esophagus.
Natsugoe S; Xiangming C; Matsumoto M; Okumura H; Nakashima S; Sakita H; Ishigami S; Baba M; Takao S; Aikou T
Clin Cancer Res; 2002 Jun; 8(6):1838-42. PubMed ID: 12060625
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical dihydropyrimidine dehydrogenase expression is a good prognostic indicator for patients with Dukes' C colorectal cancer.
Oi K; Makino M; Ozaki M; Takemoto H; Yamane N; Nakamura S; Ikeguchi M; Kaibara N
Anticancer Res; 2004; 24(1):273-9. PubMed ID: 15015608
[TBL] [Abstract][Full Text] [Related]
11. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of BMP7 in human colorectal cancer.
Motoyama K; Tanaka F; Kosaka Y; Mimori K; Uetake H; Inoue H; Sugihara K; Mori M
Ann Surg Oncol; 2008 May; 15(5):1530-7. PubMed ID: 18259822
[TBL] [Abstract][Full Text] [Related]
13. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
Aschele C; Debernardis D; Tunesi G; Maley F; Sobrero A
Clin Cancer Res; 2000 Dec; 6(12):4797-802. PubMed ID: 11156237
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Baraniskin A; Munding J; Schulmann K; Meier D; Porschen R; Arkenau HT; Graeven U; Schmiegel W; Tannapfel A; Reinacher-Schick A
Clin Colorectal Cancer; 2011 Mar; 10(1):24-9. PubMed ID: 21609932
[TBL] [Abstract][Full Text] [Related]
16. Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information.
Ohrling K; Edler D; Hallström M; Ragnhammar P; Blomgren H
J Clin Oncol; 2005 Aug; 23(24):5628-34. PubMed ID: 16009948
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
[TBL] [Abstract][Full Text] [Related]
18. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
Xi Y; Formentini A; Nakajima G; Kornmann M; Ju J
Oncol Rep; 2008 Jan; 19(1):257-62. PubMed ID: 18097604
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma.
Ren DN; Kim IY; Koh SB; Chang SJ; Eom M; Yi SY; Seong SH; Kim MD; Bronner MP; Cho MY
J Surg Oncol; 2009 Dec; 100(7):546-52. PubMed ID: 19722231
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
